DHA / DOH / MOH exam (UAE) respiratory medicine questions

Long-term high-dose inhaled corticosteroids cause systemic absorption sufficient to reduce osteoblast activity and increase bone resorption, lowering bone mineral density and increasing fracture risk, especially with cumulative doses over years. The T-score of -2.7 confirms osteoporosis. Patients on prolonged high-dose ICS should have bone density monitored and receive calcium, vitamin D, and bisphosphonates if indicated. Adrenal suppression, not thyroid axis suppression, is the other recognized systemic effect of long-term high-dose ICS.

• A. Nephrocalcinosis is not a recognized complication of inhaled corticosteroid therapy.
• C. ICS does not cause significant systemic potassium disturbance at typical doses.
• D. ICS affects the hypothalamic-pituitary-adrenal axis, not the thyroid axis.

A short-acting beta-2 agonist such as salbutamol inhaled 10-15 minutes before exercise is the most effective and rapid prophylaxis for exercise-induced bronchoconstriction, providing protection for 2-4 hours via bronchial smooth muscle relaxation. Leukotriene receptor antagonists can help but take longer to act and are less effective as single pre-exercise doses. Long-acting beta-agonists are not recommended for on-demand pre-exercise use alone, and inhaled corticosteroids have no immediate bronchodilator effect.

• B. Inhaled corticosteroids do not provide acute bronchodilation and are not useful for immediate pre-exercise prevention.
• C. Salmeterol has a delayed onset of action and is not appropriate for immediate pre-exercise protection.
• D. Montelukast has a slower onset and is better suited to regular prophylactic use than single pre-exercise dosing.

The diagnosis of COPD requires a post-bronchodilator FEV1/FVC ratio below 0.70, confirming persistent airflow limitation that is not fully reversible, in a patient with compatible symptoms and risk factor exposure such as smoking. This patient's ratio of 0.56 meets this criterion. A significant bronchodilator response favors asthma rather than confirming COPD. Hyperinflation and reduced diffusion capacity can support the diagnosis and assess severity but are not the defining diagnostic criterion.

• A. Hyperinflation supports but does not define the diagnosis of COPD.
• B. A significant bronchodilator response suggests reversible airflow obstruction, more typical of asthma, not a defining feature of COPD.
• D. Reduced diffusion capacity reflects emphysema severity but is not the diagnostic criterion for COPD.

This patient has high symptom burden (CAT score 24, mMRC grade 3) but low exacerbation risk, placing her in GOLD Group B, for which initial therapy is a long-acting muscarinic antagonist combined with a long-acting beta-agonist to maximize bronchodilation and symptom relief. Her low blood eosinophil count and absence of exacerbations do not support adding inhaled corticosteroid, which is reserved for patients with frequent exacerbations or high eosinophil counts. Short-acting bronchodilator alone is insufficient for her symptom severity. Triple therapy is reserved for Group E patients with continued exacerbations despite dual bronchodilator therapy.

• B. Triple therapy is reserved for patients with ongoing exacerbations despite dual bronchodilator therapy, not for this low-exacerbation-risk patient.
• C. As-needed short-acting bronchodilator alone is inadequate for a patient with high symptom burden.
• D. Inhaled corticosteroid monotherapy is never used alone in COPD regardless of eosinophil count.

Per the classic Anthonisen criteria, antibiotics are indicated in a COPD exacerbation when at least two of three cardinal symptoms are present: increased dyspnea, increased sputum volume, and increased sputum purulence, or when increased purulence occurs alone with one other cardinal symptom, as increased purulence is the best clinical marker of bacterial infection. This patient has both increased purulence and increased volume, meeting criteria for antibiotic therapy. Mild hypoxia and tachypnea reflect exacerbation severity but do not by themselves indicate a bacterial cause requiring antibiotics. Dyspnea alone, without sputum change, is the weakest indicator of bacterial etiology.

• A. Tachypnea reflects respiratory distress but is not a specific marker for bacterial infection.
• C. Dyspnea alone, without accompanying sputum changes, does not meet criteria for antibiotic therapy.
• D. Oxygen saturation reflects severity of the exacerbation but does not indicate a bacterial cause requiring antibiotics.

In patients with COPD and chronic hypercapnia, a controlled oxygen saturation target of 88-92% is used because over-oxygenation can worsen ventilation-perfusion mismatch, reduce the hypoxic drive to breathe, and increase dead space via the Haldane effect, all of which raise PaCO2 and risk CO2 narcosis. Higher targets such as 94-98% are appropriate for the general population without risk of hypercapnic respiratory failure but are unsafe in known or at-risk CO2 retainers. Oxygen saturation above 98% increases this risk further, while targets below 85% risk clinically significant hypoxemia.

• A. Saturation above 98% increases the risk of oxygen-induced hypercapnia and CO2 narcosis.
• B. This target risks significant tissue hypoxia and is lower than necessary even in CO2 retainers.
• C. This target is used in patients without risk of hypercapnic respiratory failure and risks worsening CO2 retention in COPD patients.

Non-invasive positive pressure ventilation is indicated in a COPD exacerbation when there is persistent respiratory acidosis with pH below 7.35 and PaCO2 above 45 mmHg despite initial medical therapy, as it reduces the work of breathing, improves alveolar ventilation, and lowers the need for intubation and associated mortality. This patient's pH of 7.28 and PaCO2 of 68 mmHg after an hour of standard therapy meet these criteria. Increasing oxygen flow without addressing ventilation would worsen hypercapnia. Invasive ventilation is reserved for NIV failure, severe consciousness impairment, or inability to tolerate a mask, and aminophylline is not recommended as routine exacerbation therapy due to limited benefit and toxicity risk.

• B. Intravenous aminophylline has an unfavorable risk-benefit profile and is not recommended as standard exacerbation therapy.
• C. Raising oxygen alone does not address the ventilatory failure and risks worsening hypercapnia.
• D. Invasive ventilation is reserved for patients who fail or cannot tolerate non-invasive ventilation, not as the initial step.

Isoniazid inhibits pyridoxine (vitamin B6)-dependent enzymes involved in GABA synthesis and competes with pyridoxal phosphate, leading to functional B6 deficiency and peripheral neuropathy. Patients with risk factors such as diabetes mellitus, alcohol use, malnutrition, HIV infection, pregnancy, or chronic kidney disease are given prophylactic pyridoxine throughout treatment. This diabetic patient is at increased baseline risk of neuropathy, making pyridoxine supplementation standard practice. Dose is typically 10-25 mg daily alongside isoniazid.

• A. Cyanocobalamin treats vitamin B12 deficiency, which is not the mechanism of isoniazid-induced neuropathy.
• C. Thiamine deficiency causes beriberi and Wernicke's encephalopathy, unrelated to isoniazid toxicity.
• D. Folic acid prevents neural tube defects and some drug-induced megaloblastic anemia, not isoniazid neuropathy.

Ethambutol can cause dose-dependent optic neuritis, presenting with decreased visual acuity, loss of red-green color discrimination, and central or peripheral scotomas. Baseline visual acuity and color vision (using an Ishihara chart) should be documented before starting therapy and monitored monthly, especially in patients on higher doses or with renal impairment. Early detection and prompt discontinuation of ethambutol usually reverses the toxicity. Patients should be counseled to report any visual changes immediately.

• B. Intraocular pressure measurement screens for glaucoma, unrelated to ethambutol-induced optic neuritis.
• C. Cataract formation is not a known adverse effect of ethambutol therapy.
• D. Papilledema is associated with raised intracranial pressure, not a recognized ethambutol toxicity.

Interferon-gamma release assays (IGRA) use antigens specific to Mycobacterium tuberculosis (ESAT-6 and CFP-10) that are absent from the BCG vaccine strain, giving IGRA better specificity than the tuberculin skin test in BCG-vaccinated populations such as those in the UAE. A positive IGRA in an asymptomatic person with a normal chest X-ray confirms latent TB infection, which should be treated with isoniazid preventive therapy (typically 6-9 months) after excluding active disease. IGRA also avoids the reader-dependent variability and need for a return visit associated with the tuberculin skin test.

• A. Sputum AFB smear detects active pulmonary disease with bacillary shedding, not latent infection.
• B. Chest CT is not used to diagnose latent infection and would be normal in latent TB.
• C. The tuberculin skin test cross-reacts with BCG vaccination, reducing specificity in vaccinated populations.

UAE health authorities (DHA, DOH, MOHAP) require a chest X-ray as part of the standard medical fitness test for all residency visa applicants to screen for active pulmonary tuberculosis and other significant chest pathology. Individuals with an abnormal chest X-ray suggestive of active TB are referred for further work-up, including sputum microscopy and culture, before a final fitness decision is made. This radiographic screening is a cost-effective, rapid method suited to mass pre-employment and visa screening programs. It is not intended to detect latent infection.

• B. IGRA detects latent infection and is not part of the standard UAE visa medical fitness screening protocol.
• C. Sputum culture is reserved for individuals with an abnormal chest X-ray or symptoms, not for routine mass screening.
• D. The tuberculin skin test is not used in the routine UAE visa medical fitness screening program.

Hemoptysis, unexplained weight loss, and a persistent cough lasting more than 3 weeks unresponsive to treatment in a smoker over 40 years old are red-flag features warranting urgent chest imaging to exclude lung cancer, following international guidelines such as NICE. An urgent chest X-ray is the recommended first investigation and should be obtained within 2 weeks, with onward referral for CT and tissue diagnosis if abnormal or if clinical suspicion remains high despite a normal film. Delayed investigation in this high-risk population risks missing a potentially curable early-stage malignancy. Smoking history and age further raise pre-test probability.

• A. Sputum culture targets infection, not malignancy, and does not explain hemoptysis with weight loss in this risk profile.
• C. Reassurance and delayed review is inappropriate given red-flag symptoms suggesting possible malignancy.
• D. Bronchodilators do not address the underlying cause and would delay diagnosis in a red-flag presentation.

A tissue biopsy, obtained via bronchoscopy for centrally located masses or CT-guided percutaneous biopsy for peripheral lesions, is required to establish a definitive histological diagnosis of suspected lung cancer and to guide molecular and treatment planning. Sputum cytology has low sensitivity and cannot reliably characterize tumor subtype or molecular markers needed for targeted therapy. PET scanning is valuable for staging and assessing metabolic activity but does not provide a histological diagnosis. Biopsy results determine whether the tumor is small cell or non-small cell and guide further management including surgery, chemotherapy, or targeted agents.

• A. Sputum cytology has low sensitivity for peripheral lesions and cannot reliably confirm tumor type.
• B. PET scan assists in staging and metabolic assessment but does not give a tissue diagnosis.
• D. Repeating imaging delays diagnosis and does not provide histological confirmation needed for management.

Small cell lung carcinoma arises from neuroendocrine cells and frequently secretes ectopic antidiuretic hormone, causing the syndrome of inappropriate antidiuretic hormone secretion (SIADH). This produces euvolemic hyponatremia with inappropriately concentrated urine, as seen in this patient with low serum osmolality but high urine osmolality and urine sodium above 20 mmol/L. Squamous cell carcinoma is more classically associated with hypercalcemia due to parathyroid hormone-related peptide secretion, not SIADH. Management involves fluid restriction and treating the underlying malignancy, with careful correction of sodium to avoid osmotic demyelination syndrome.

• B. Squamous cell carcinoma is classically linked to hypercalcemia via PTH-related peptide, not SIADH.
• C. Carcinoid tumors are more classically linked to carcinoid syndrome with flushing and diarrhea, not SIADH.
• D. Adenocarcinoma is not typically associated with ectopic ADH secretion causing SIADH.

This patient has classic signs of tension pneumothorax: hypotension, tracheal deviation away from the affected side, absent breath sounds, and distended neck veins from impaired venous return. Tension pneumothorax is a clinical diagnosis and demands immediate decompression without waiting for imaging, since delay can cause cardiac arrest from obstructive shock. Needle decompression is performed in the second intercostal space at the midclavicular line (or alternatively the fifth intercostal space, anterior axillary line) on the affected side, followed by definitive tube thoracostomy. Imaging would only delay life-saving treatment in this unstable patient.

• A. Echocardiography is not the priority and delays decompression in an emergency diagnosed clinically.
• B. Imaging delays life-saving treatment in a clinically unstable patient and is not required for diagnosis.
• D. Fluids and oxygen do not relieve the mechanical obstruction and the patient will deteriorate without decompression.

Light's criteria classify a pleural effusion as an exudate if any one of the following is present: pleural fluid to serum protein ratio greater than 0.5, pleural fluid to serum LDH ratio greater than 0.6, or pleural fluid LDH greater than two-thirds the upper limit of normal serum LDH. In this case, the pleural fluid protein (45 g/L) divided by serum protein (68 g/L) equals 0.66, exceeding 0.5, confirming an exudate. The LDH ratio (250/180 = 1.39) also exceeds 0.6, further supporting this classification. Glucose and pH values help identify complicated effusions or empyema but are not part of Light's criteria for exudate versus transudate distinction.

• B. Pleural fluid pH is used to guide drainage decisions in parapneumonic effusions, not to classify exudate versus transudate.
• C. Glucose level is used to assess for complicated effusion or malignancy, not to apply Light's criteria.
• D. Red blood cell count helps suggest hemothorax or malignancy but is not part of Light's criteria.

Diagnostic thoracentesis is the best initial test for a new, undiagnosed pleural effusion because fluid analysis (protein, LDH, glucose, pH, cell count, cytology, and microbiology) rapidly narrows the differential between infection, malignancy, and other causes. In a smoker with an unexplained effusion, malignancy must be excluded, and cytological examination of pleural fluid can be diagnostic. CT imaging is complementary and helpful for further characterization but does not replace fluid sampling. Empiric treatment without a tissue or fluid diagnosis risks missing a significant underlying condition such as malignant effusion or tuberculosis.

• A. Corticosteroids without a diagnosis could worsen an infectious or malignant process and delay appropriate treatment.
• B. CT chest is useful for staging and characterization but does not provide biochemical or cytological diagnosis without fluid sampling.
• D. Empiric antibiotics without a confirmed diagnosis risk delaying identification of a serious underlying cause such as malignancy.

Idiopathic pulmonary fibrosis (IPF) typically presents in older adults with progressive dyspnea, dry cough, bibasilar fine crackles, and clubbing. The HRCT pattern of basal and subpleural predominant reticulation with honeycombing and traction bronchiectasis, in the absence of features suggesting an alternative diagnosis, defines a usual interstitial pneumonia (UIP) pattern, which is diagnostic of IPF when clinical context is consistent. Pulmonary function tests characteristically show a restrictive pattern with reduced diffusion capacity for carbon monoxide (DLCO). No exposure history or extrapulmonary findings point toward an alternative interstitial lung disease.

• A. Hypersensitivity pneumonitis typically shows upper/mid-zone or diffuse ground-glass and mosaic attenuation, usually with an identifiable antigen exposure, which is absent here.
• B. COPD causes an obstructive, not restrictive, pattern on pulmonary function testing and does not produce honeycombing on HRCT.
• D. Sarcoidosis typically involves hilar lymphadenopathy and upper-zone predominant nodular opacities, not basal honeycombing.

Silicosis results from chronic inhalation of crystalline silica dust, commonly encountered in sandblasting, mining, and stone-cutting occupations. It characteristically produces upper lobe predominant small rounded nodular opacities on chest imaging, and eggshell calcification of hilar lymph nodes is a classic, though not universal, finding. The silica particles are engulfed by alveolar macrophages, triggering fibrogenic inflammation and nodule formation. This occupational history and radiographic pattern distinguish silicosis from asbestos-related disease, which typically causes lower zone fibrosis and pleural plaques.

• A. Beryllium exposure causes berylliosis, which mimics sarcoidosis radiographically but is linked to specific industries like aerospace and electronics, not sandblasting.
• B. Coal dust exposure causes coal worker's pneumoconiosis, which produces diffuse small nodular opacities but is not classically linked with eggshell calcification.
• D. Asbestos exposure typically causes lower zone interstitial fibrosis and pleural plaques, not upper zone nodules with eggshell calcification.

Hypersensitivity pneumonitis (extrinsic allergic alveolitis) results from repeated inhalation of organic antigens, such as avian proteins in bird fancier's lung, triggering an immune-mediated inflammatory reaction in the lung parenchyma and small airways. The clinical pattern of symptoms recurring with exposure and improving with avoidance, combined with HRCT findings of ground-glass opacity, mosaic attenuation, and centrilobular nodules, is characteristic. Diagnosis is supported by exposure history, serum precipitins against the specific antigen, and bronchoalveolar lavage lymphocytosis when needed. Avoidance of the antigen is the cornerstone of management alongside corticosteroids in symptomatic or persistent disease.

• B. Allergic bronchopulmonary aspergillosis occurs in patients with asthma or cystic fibrosis and presents with central bronchiectasis and mucus plugging, not this exposure pattern.
• C. Pneumonia would not show this recurrent exposure-related pattern with resolution upon avoidance of pigeons.
• D. Churg-Strauss syndrome presents with asthma, eosinophilia, and vasculitic features, not an exposure-dependent respiratory illness.

The STOP-BANG questionnaire is a validated screening tool for obstructive sleep apnea (OSA) that assesses snoring, tiredness, observed apnea, blood pressure, BMI, age, neck circumference, and gender; a high score indicates high pretest probability of OSA. However, screening tools identify risk and do not confirm the diagnosis. Overnight polysomnography, which records respiratory effort, airflow, oxygen saturation, and sleep staging, remains the gold-standard confirmatory test, quantifying the apnea-hypopnea index to establish diagnosis and severity. Home sleep apnea testing is an acceptable alternative in selected uncomplicated patients, but polysomnography remains the reference standard, especially when comorbidities are present.

• A. Arterial blood gas analysis may show hypercapnia in severe or chronic cases but does not diagnose or quantify sleep apnea.
• B. Spirometry evaluates lung mechanics and helps exclude obstructive or restrictive lung disease but does not diagnose OSA.
• D. Pulse oximetry alone can suggest desaturation episodes but lacks the detail needed to calculate the apnea-hypopnea index and confirm diagnosis.

Continuous positive airway pressure (CPAP) is the first-line treatment for moderate-to-severe obstructive sleep apnea (AHI ≥15/hour). It works by pneumatically splinting the upper airway open throughout the respiratory cycle, preventing collapse of the pharyngeal soft tissues during sleep. CPAP reduces AHI, improves oxygen saturation, reduces daytime sleepiness, and lowers cardiovascular risk associated with OSA. Oral appliances and surgery are reserved for mild OSA, CPAP intolerance, or specific anatomical indications.

• A. Modafinil treats residual daytime sleepiness after adequate CPAP therapy, not the underlying airway obstruction.
• C. Mandibular advancement devices are recommended for mild OSA or CPAP-intolerant patients, not first-line for moderate-to-severe disease.
• D. Surgery is reserved for anatomical obstruction or CPAP failure, not as initial therapy.

Acute epiglottitis classically presents with rapid onset high fever, sore throat, muffled 'hot potato' voice, drooling due to painful swallowing, and the tripod position (sitting forward, neck extended) to maximize airway patency. It is typically caused by Haemophilus influenzae type b in unvaccinated children and is a true airway emergency requiring urgent airway management in a controlled setting rather than throat examination or lateral neck X-ray. Croup, in contrast, has a barking cough and stridor with a more gradual viral prodrome.

• B. Croup presents with a barking cough and inspiratory stridor following a viral prodrome, which is absent here.
• C. Bacterial tracheitis usually follows a preceding viral illness with a brassy cough and does not classically cause drooling or tripod positioning.
• D. Retropharyngeal abscess causes neck stiffness and torticollis rather than drooling with tripod positioning and muffled voice as the dominant features.

High-resolution computed tomography (HRCT) of the chest is the gold-standard investigation for diagnosing bronchiectasis. It demonstrates characteristic findings including bronchial dilatation with a lumen wider than the accompanying pulmonary artery (signet ring sign), lack of tapering of airways, and parallel bronchial walls (tram-track sign). Chest X-ray lacks the sensitivity to reliably detect these changes. Sputum culture and spirometry are useful for management and monitoring but do not establish the structural diagnosis.

• A. Spirometry assesses functional airflow obstruction and is useful for monitoring but cannot diagnose the anatomical airway dilatation.
• C. Bronchoscopy may identify a localized cause or obtain samples but is not the standard diagnostic test for bronchiectasis.
• D. Sputum culture identifies causative organisms for exacerbations but does not establish the structural diagnosis of bronchiectasis.

An acute exacerbation of bronchiectasis in a hemodynamically stable patient is managed with empirical oral antibiotics guided by local resistance patterns and prior sputum culture history, started promptly without waiting for current culture results, which are later adjusted once sensitivities return. Airway clearance techniques should be intensified during exacerbations. Intravenous antibiotics and hospital admission are reserved for patients who fail oral therapy, have severe exacerbations, or are hemodynamically unstable.

• B. Inhaled corticosteroids do not treat acute bacterial exacerbations and are not first-line for exacerbation management.
• C. Intravenous antibiotics and admission are reserved for severe exacerbations or oral treatment failure, not a stable outpatient presentation.
• D. Surgery is reserved for localized disease with recurrent severe hemoptysis or infections refractory to medical therapy, not for routine exacerbations.

The Berlin definition of ARDS requires onset within one week of a known clinical insult, bilateral opacities on chest imaging not fully explained by effusion, collapse, or nodules, respiratory failure not fully explained by cardiac failure or fluid overload, and a PaO2/FiO2 ratio ≤300 mmHg with PEEP ≥5 cmH2O. This patient's PaO2/FiO2 ratio is 68/0.6 = 113 mmHg, meeting criteria for moderate ARDS, with acute pancreatitis as the precipitating insult and echocardiography excluding a cardiogenic cause. This distinguishes ARDS from cardiogenic edema, which is specifically excluded by the Berlin criteria.

• A. Cardiogenic pulmonary edema is excluded by the normal left ventricular function and absence of fluid overload on echocardiography.
• B. Pulmonary embolism classically causes focal perfusion defects rather than bilateral diffuse infiltrates and would not explain this presentation as well as ARDS.
• C. Pneumonia typically causes focal or lobar infiltrates rather than bilateral diffuse opacities following a non-pulmonary systemic insult.

A falling respiratory rate, silent chest, altered consciousness, and persistent hypoxemia despite high-flow oxygen in severe asthma indicate impending respiratory arrest and are absolute indications for immediate endotracheal intubation and mechanical ventilation. A silent chest signals minimal air movement rather than improvement, and drowsiness reflects hypercapnic narcosis or hypoxemia. Delaying definitive airway control in this setting risks respiratory arrest. Non-invasive ventilation is contraindicated in a patient with reduced consciousness and impending arrest because it cannot protect the airway.

• B. Magnesium sulfate is an adjunct bronchodilator therapy but does not address the immediate need for airway protection in impending respiratory arrest.
• C. Further nebulized therapy is inadequate given the silent chest and declining consciousness, which indicate the patient is not moving air effectively.
• D. Non-invasive ventilation is contraindicated in a drowsy patient with impending respiratory arrest due to inability to protect the airway.

Adrenaline is the first-line drug in anaphylaxis because it acts on multiple adrenergic receptors simultaneously. Alpha-1 agonism causes peripheral vasoconstriction, raising blood pressure and reducing mucosal oedema and angioedema, while beta-2 agonism produces bronchodilation and relaxes airway smooth muscle, relieving wheeze and stridor. Beta-1 agonism also increases heart rate and myocardial contractility, supporting cardiac output in distributive shock. It additionally stabilises mast cells and basophils, reducing further mediator release, but this is a secondary rather than the primary immediate effect.

• A. This describes mast cell stabilisers like cromolyn, not the rapid receptor-mediated action of adrenaline.
• B. Antihistamines target histamine receptors but do not raise blood pressure or reverse bronchospasm acutely.
• C. Adrenaline stimulates, not blocks, beta-1 receptors, increasing rather than decreasing heart rate and contractility.

Asthma is characterized by variable airflow limitation, and excessive variability in peak expiratory flow (typically more than 10% diurnal variation, or more than 13-15% in some criteria) over days to weeks is a key supportive feature according to GINA. A single low reading does not establish variability and could reflect many other conditions. Bibasilar crackles suggest an interstitial or fibrotic process, not asthma. Bilateral hilar lymphadenopathy points toward sarcoidosis or lymphoma, not asthma.

• A. Hilar lymphadenopathy is not a feature of asthma and suggests an alternative diagnosis such as sarcoidosis.
• B. Bibasilar crackles suggest a different pathology such as pulmonary fibrosis or heart failure, not asthma.
• C. A single reading only shows the flow at one point in time and cannot demonstrate variability, which is the hallmark of asthma.

Current GINA guidance recommends as-needed low-dose inhaled corticosteroid-formoterol (such as budesonide-formoterol) as the preferred reliever for all adults and adolescents with asthma, including those with infrequent symptoms, rather than a short-acting beta agonist alone. This approach reduces the risk of severe exacerbations compared with SABA-only reliever use, because every symptomatic dose also delivers anti-inflammatory treatment. Regular daily ICS with as-needed SABA remains an alternative but is no longer the preferred first option. Montelukast is not recommended as reliever therapy in asthma.

• B. Montelukast is an oral leukotriene receptor antagonist used as add-on controller therapy, not an as-needed reliever.
• C. Daily maintenance ICS with as-needed SABA is an alternative but not the preferred first option in current GINA guidance for mild asthma.
• D. SABA-only reliever therapy is no longer preferred because it provides no anti-inflammatory effect and is linked to higher exacerbation risk.

When asthma remains poorly controlled despite good adherence and technique on low-dose inhaled corticosteroid, the recommended step-up in GINA track 1 is to combine the low-dose inhaled corticosteroid with a long-acting beta-agonist, typically as a combination inhaler such as budesonide-formoterol used for both maintenance and relief. This combination improves symptom control and lung function more effectively than increasing ICS dose alone. Oral leukotriene antagonists are less effective than ICS-LABA as a step-up option. Oral corticosteroids are reserved for exacerbations, not for routine step-up of chronic poorly controlled asthma.

• A. Switching to an oral leukotriene antagonist alone is a less effective option and would mean stopping inhaled corticosteroid therapy, which is not appropriate here.
• B. Simply increasing the ICS dose alone is less effective than adding a LABA at this step according to GINA.
• D. Oral corticosteroids are used for acute exacerbations, not as a next step for chronic step-up in a stable outpatient with persistent symptoms.

A silent chest, where wheeze is absent despite severe airflow obstruction, indicates such severe bronchoconstriction that little air movement occurs to generate breath sounds, and combined with exhaustion it is a hallmark life-threatening feature of asthma. Tachypnea above 25/min, tachycardia above 110/min, and inability to complete sentences are features of acute severe asthma but do not by themselves meet life-threatening criteria. Life-threatening features include silent chest, cyanosis, bradycardia, hypotension, exhaustion, confusion, or SpO2 below 92% with a low PaO2.

• B. Inability to complete sentences is a feature of severe asthma, not specific to the life-threatening category.
• C. A respiratory rate above 25/min is a marker of severe, not necessarily life-threatening, asthma.
• D. A heart rate above 110/min is a marker of severe asthma but is not itself a life-threatening criterion.

After securing oxygenation, the next step in acute severe asthma is nebulized short-acting beta-agonist combined with a short-acting anticholinergic such as ipratropium bromide, which produces greater bronchodilation than salbutamol alone and reduces the need for hospital admission. Systemic corticosteroids should also be given early, but antibiotics are not routinely indicated unless there is clear evidence of bacterial infection. Imaging is not a first step and should not delay bronchodilator therapy. Long-acting beta-agonists have a slower onset and are not appropriate for acute rescue treatment.

• A. Imaging is not part of first-line management and should not delay bronchodilator and steroid therapy.
• B. Antibiotics are not routinely indicated in acute asthma exacerbations unless there is evidence of bacterial infection.
• C. Long-acting beta-agonists have a delayed onset of action and are unsuitable for acute rescue treatment.

Intravenous magnesium sulfate is indicated in severe or life-threatening asthma exacerbations that respond poorly to initial nebulized bronchodilators and systemic corticosteroids, acting as a smooth muscle relaxant that produces additional bronchodilation. It is typically given as a single infusion over 20 minutes. Furosemide has no role in asthma and is used for pulmonary edema. Oral theophylline is not recommended in the acute setting due to a narrow therapeutic index and limited added benefit, and intramuscular adrenaline is reserved for anaphylaxis, not for asthma exacerbations without anaphylactic features.

• B. Furosemide is a diuretic used for pulmonary edema and has no bronchodilator role in asthma.
• C. Theophylline has a narrow therapeutic index and limited additional benefit in acute severe asthma, so it is not recommended as next-line therapy.
• D. Intramuscular adrenaline is used for anaphylaxis, not for an asthma exacerbation without features of anaphylaxis.

Long-term oxygen therapy (LTOT) in COPD is indicated when resting PaO2 is ≤ 55 mmHg (7.3 kPa) on room air, confirmed by two arterial blood gas measurements taken at least three weeks apart during a period of clinical stability. A PaO2 of 56-59 mmHg (7.3-8.0 kPa) qualifies only if there is evidence of secondary polycythemia, peripheral edema (cor pulmonale), or pulmonary hypertension. Pulse oximetry is used to screen for hypoxemia but cannot substitute for confirmatory arterial blood gas sampling. FEV1 and symptom severity guide overall COPD management but do not by themselves determine LTOT eligibility.

• A. Spirometric severity reflects airflow obstruction but is not part of the oxygen prescription criteria.
• B. Exercise limitation assesses functional status, not the arterial oxygen tension used to qualify for LTOT.
• C. A single oximetry reading is a screening tool, not a diagnostic criterion, and does not confirm sustained hypoxemia.

Smoking cessation is the only intervention proven to slow the accelerated decline in FEV1 and alter the natural history of COPD; the rate of decline in quitters approaches that of non-smokers over time. Bronchodilators improve symptoms, exercise tolerance, and reduce exacerbation frequency but do not modify the underlying rate of lung function decline. Influenza vaccination reduces exacerbation risk and mortality from respiratory infection but has no effect on disease progression. Pulmonary rehabilitation improves quality of life, dyspnea, and exercise capacity without altering the trajectory of airflow decline.

• A. Bronchodilators relieve symptoms and reduce exacerbations but do not slow the decline in FEV1.
• B. Vaccination prevents infection-related exacerbations but does not change the underlying disease course.
• C. Rehabilitation improves functional capacity and symptoms but has no proven effect on FEV1 decline.

Early-onset emphysema in a non-smoker, especially with a basal predominance pattern and a family history of unexplained liver disease, is a classic presentation of alpha-1 antitrypsin (AAT) deficiency. The initial test is a serum AAT level; low levels are followed by genotyping (e.g., for the Z and S alleles) to confirm the diagnosis. AAT deficiency causes panacinar emphysema due to unchecked neutrophil elastase activity in the lungs and can cause cirrhosis from accumulation of misfolded protein in hepatocytes. Sweat chloride testing is used for cystic fibrosis, which typically presents earlier in life with bronchiectasis and recurrent infections, not isolated basal emphysema.

• A. Bronchiectasis is not the pattern described here; the findings point to emphysema from a protease-antiprotease imbalance.
• C. IgE levels evaluate allergic or eosinophilic conditions such as allergic bronchopulmonary aspergillosis, not this presentation.
• D. Sweat chloride testing is for cystic fibrosis, which presents differently with bronchiectasis and recurrent sino-pulmonary infections.

This patient scores 4 on CURB-65: confusion (1), urea > 7 mmol/L (1), respiratory rate ≥ 30 is not met but systolic BP < 90 mmHg or diastolic ≤ 60 mmHg counts (1), and age ≥ 65 years (1); his respiratory rate of 24 does not add a point, giving a total of 4. A CURB-65 score of 3-5 indicates severe pneumonia with high mortality risk, requiring hospital admission and consideration of intensive care assessment. Scores of 0-1 are suitable for outpatient treatment, and a score of 2 warrants a short inpatient stay or closely supervised outpatient treatment. This patient's hypotension and confusion further support urgent admission regardless of the exact score breakdown.

• B. A CURB-65 score of 4 indicates severe pneumonia with significant mortality risk, which is unsafe to manage as an outpatient.
• C. His severity score and hemodynamic instability require full inpatient assessment and treatment, not an outpatient-equivalent regimen.
• D. He requires acute assessment and admission first; bypassing emergency evaluation for a step-down unit is inappropriate and unsafe.

For low-severity community-acquired pneumonia (CURB-65 score 0-1) in a patient with no comorbidities, oral amoxicillin is the first-line empirical antibiotic because Streptococcus pneumoniae remains the most common causative organism and amoxicillin provides reliable coverage with a narrow spectrum. Doxycycline or a macrolide are reasonable alternatives in penicillin-allergic patients or when atypical organisms are suspected. Fluoroquinolones such as ciprofloxacin have poor pneumococcal activity and are not first-line for CAP; combination intravenous regimens are reserved for moderate-to-severe disease requiring hospital admission.

• A. This combination is unnecessarily broad and parenteral for a patient with mild, low-risk community-acquired pneumonia.
• B. Intravenous combination therapy is reserved for moderate-to-severe CAP requiring hospitalization, not low-severity outpatient disease.
• C. Ciprofloxacin has weak activity against Streptococcus pneumoniae and is not recommended for CAP.

This presentation is characteristic of Mycoplasma pneumoniae infection: a young adult in a closed community setting with a prolonged dry cough, minimal findings on examination disproportionate to extensive bilateral interstitial infiltrates on imaging, and clustering of cases among close contacts. Mycoplasma lacks a cell wall, so beta-lactam antibiotics such as amoxicillin, flucloxacillin, and penicillin are ineffective. Macrolides such as azithromycin, or alternatively doxycycline, are the treatment of choice because they target bacterial protein synthesis rather than cell wall formation.

• A. Flucloxacillin is a beta-lactam with the same mechanism limitation and no activity against atypical organisms like Mycoplasma.
• B. Penicillin acts on the bacterial cell wall and has no activity against Mycoplasma pneumoniae.
• C. Amoxicillin targets cell wall synthesis, which is ineffective against Mycoplasma, an organism lacking a cell wall.

The silhouette sign states that when two structures of similar radiographic density are in direct contact, their shared border is obscured on X-ray; when they are separated by aerated lung, the border remains visible. The right middle lobe lies against the right heart border, so middle lobe consolidation obscures the cardiac silhouette while sparing the diaphragm outline. The right lower lobe lies posteriorly against the diaphragm but not against the heart border, so lower lobe consolidation obscures the diaphragm while the cardiac border stays sharp, as described in this case. This sign helps localize the lobe involved without needing a lateral film or CT.

• A. Air-fluid levels indicate cavitation or abscess formation, which is not described in this straightforward consolidation.
• B. Tracheal deviation relates to large volume loss or mass effect, not the silhouette finding described in this scenario.
• C. A widened mediastinum is not described here and would suggest a different process such as aortic pathology, not a lobar pneumonia pattern.

Hospital-acquired pneumonia (pneumonia occurring more than 48 hours after admission) carries a higher risk of multidrug-resistant organisms, particularly Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus, compared with community-acquired pneumonia. Empirical regimens therefore typically combine an antipseudomonal beta-lactam (such as piperacillin-tazobactam or cefepime) with an agent active against MRSA (such as vancomycin or linezolid), especially in patients with risk factors for resistant pathogens. This differs from CAP, where coverage targets Streptococcus pneumoniae, Haemophilus influenzae, and atypical organisms. Local antibiogram data should guide the final choice of agents.

• A. Oral amoxicillin-clavulanate is inadequate for hospital-acquired pneumonia and does not address resistant nosocomial pathogens.
• B. Macrolide monotherapy does not cover the gram-negative and MRSA pathogens common in hospital-acquired pneumonia.
• C. Gram-negative coverage, including Pseudomonas, is essential in hospital-acquired pneumonia given the higher prevalence of resistant organisms.

Frank pus, pleural fluid pH below 7.2, and low glucose define empyema, which requires tube thoracostomy drainage in addition to continued antibiotics. Antibiotics alone cannot penetrate the loculated purulent collection effectively, and delayed drainage increases the risk of fibrothorax and prolonged illness. Image-guided chest tube placement, sometimes combined with intrapleural fibrinolytics for loculated collections, is the standard of care. Surgical decortication is reserved for cases that fail tube drainage.

• A. Antibiotic dose escalation alone does not address the mechanical need to evacuate frank pus from the pleural space.
• B. Corticosteroids have no established role in the management of empyema and do not replace drainage.
• C. Repeated diagnostic thoracentesis without definitive drainage delays resolution of an established empyema.

Dysphagia and impaired airway protection, common after stroke, predispose to aspiration of oropharyngeal secretions, which follow gravity into the right lower lobe because of the more vertical and wider right main bronchus. Aspirated material carries mixed anaerobic and aerobic oral flora, producing the characteristic foul-smelling sputum and often a necrotizing or cavitating pneumonia if untreated. Risk factors include altered consciousness, dysphagia, poor dentition, and gastroesophageal reflux. Antibiotic coverage should therefore include anaerobic activity, such as amoxicillin-clavulanate or clindamycin.

• A. Reactivation tuberculosis classically localizes to the upper lobes and presents with a chronic course, not an acute foul-smelling infiltrate.
• B. Mycoplasma pneumoniae causes an atypical pneumonia unrelated to swallowing dysfunction and does not produce foul-smelling sputum.
• C. Hematogenous spread from endocarditis typically causes multifocal or septic emboli rather than a single lower lobe infiltrate with foul sputum.

Current guidelines recommend pneumococcal vaccination for adults aged 65 years and older and for younger adults with chronic conditions such as diabetes mellitus, chronic lung or heart disease, or immunocompromise, because these groups have higher rates of invasive pneumococcal disease. Annual influenza vaccination is also recommended for this same high-risk population, since influenza infection increases the risk of secondary bacterial pneumonia. Combining both vaccines reduces the overall burden of respiratory infection and its complications in at-risk adults. Diabetes alone is sufficient indication for both vaccines regardless of age cutoffs.

• B. Preventive vaccination should be given proactively, not deferred until illness develops.
• C. Influenza vaccination is specifically recommended in patients with diabetes because of their increased risk of complications.
• D. Pneumococcal vaccination is indicated well before age 70 in patients with chronic conditions such as diabetes.

A chronic cough lasting more than 2 weeks, accompanied by hemoptysis, unintentional weight loss, and drenching night sweats, is the classic symptom complex of pulmonary tuberculosis, especially in a patient from a high-burden region such as South Asia. These constitutional symptoms reflect the chronic granulomatous inflammatory response to Mycobacterium tuberculosis. Occupational exposure in crowded worker accommodations further raises pretest probability. This presentation should prompt immediate respiratory isolation and microbiological testing rather than empirical treatment for other conditions.

• A. Bacterial pneumonia usually presents acutely over days rather than with a 6-week chronic course and marked weight loss.
• C. Bronchogenic carcinoma can cause weight loss and hemoptysis but is less likely at this age and does not typically cause drenching night sweats.
• D. COPD exacerbation occurs in patients with an established diagnosis of COPD and does not explain hemoptysis or systemic weight loss.

A sputum-based nucleic acid amplification test such as GeneXpert MTB/RIF is the preferred initial investigation for suspected active pulmonary tuberculosis because it rapidly detects Mycobacterium tuberculosis DNA and simultaneously identifies rifampicin resistance within hours. It has higher sensitivity than smear microscopy alone and allows faster initiation of appropriate therapy. Sputum smear for acid-fast bacilli can be used alongside it but is less sensitive and does not provide resistance information. Interferon-gamma release assays and tuberculin skin tests detect immune sensitization and cannot distinguish active disease from latent infection, so they are not used to confirm active TB.

• A. Contrast CT can characterize the cavity further but does not provide microbiological confirmation of active tuberculosis.
• C. Interferon-gamma release assays detect prior exposure or latent infection and cannot confirm active pulmonary disease.
• D. The tuberculin skin test also reflects immune sensitization rather than active disease and has lower specificity, especially after BCG vaccination.

Upper lobe or apical segment cavitation with surrounding infiltrates is the classic radiographic pattern of post-primary (reactivation) pulmonary tuberculosis, reflecting the higher oxygen tension in the apices that favors mycobacterial growth. Cavities form because of tissue necrosis from the host's immune response and can communicate with the bronchial tree, producing air-fluid levels and allowing airborne transmission through expectorated bacilli. This pattern differs from the dense, lobar consolidation of typical bacterial pneumonia, which usually resolves rather than cavitates. Recognizing this pattern should prompt urgent microbiological confirmation and infection control measures.

• A. Emphysematous bullae are thin-walled lucent spaces from parenchymal destruction and lack the surrounding infiltrate seen here.
• B. A solitary nodule is a discrete rounded opacity without cavitation and infiltrate, which does not match this description.
• C. Pneumococcal pneumonia typically produces dense lobar consolidation without cavitation in an immunocompetent host.

The standard first-line regimen for drug-susceptible pulmonary tuberculosis is a 2-month intensive phase with isoniazid, rifampicin, pyrazinamide, and ethambutol, followed by a 4-month continuation phase with isoniazid and rifampicin, for a total of 6 months. The intensive phase rapidly reduces the bacillary load and prevents the emergence of resistance, while the continuation phase eliminates remaining persister organisms. Pyrazinamide and ethambutol are dropped after the intensive phase because they do not add benefit during the continuation phase in standard drug-susceptible disease. Directly observed therapy and baseline liver function and visual acuity checks are recommended to support adherence and monitor for toxicity.

• A. Continuing all four drugs for the full 6 months exceeds standard practice and increases unnecessary toxicity risk from pyrazinamide and ethambutol.
• C. Isoniazid and rifampicin alone for 9 months omits the intensive phase drugs needed to rapidly reduce bacillary burden and is not the standard regimen.
• D. Omitting isoniazid from the intensive phase departs from the standard four-drug regimen and is not recommended for standard drug-susceptible disease.